Fresenius Kabi and Formycon have revealed that their partnered FYB202 proposed biosimilar to Stelara (ustekinumab) has now had its filing accepted by the European Medicines Agency.
Fresenius And Formycon File Ustekinumab In Europe
Application For FYB202 Biosimilar Rival To Stelara Is Accepted By EMA
Fresenius Kabi and Formycon have seen their filing for an ustekinumab biosimilar rival to Stelara accepted for review by the European Medicines Agency. A filing with the US FDA is also on the way.
